These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29915021)

  • 1. Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
    Tonneijck L; Muskiet MHA; Twisk JW; Kramer MHH; Danser AHJ; Joles JA; Smits MM; van Raalte DH
    Hypertension; 2018 Aug; 72(2):314-322. PubMed ID: 29915021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
    Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
    Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
    Tonneijck L; Muskiet MHA; Blijdorp CJ; Smits MM; Twisk JW; Kramer MHH; Danser AHJ; Diamant M; Joles JA; Hoorn EJ; van Raalte DH
    Am J Physiol Renal Physiol; 2019 Feb; 316(2):F231-F240. PubMed ID: 30353743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Diabetes Res Clin Pract; 2017 Feb; 124():1-10. PubMed ID: 28086201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
    Meier JJ; Rosenstock J; Hincelin-Méry A; Roy-Duval C; Delfolie A; Coester HV; Menge BA; Forst T; Kapitza C
    Diabetes Care; 2015 Jul; 38(7):1263-73. PubMed ID: 25887358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
    Becker RH; Stechl J; Steinstraesser A; Golor G; Pellissier F
    Diabetes Metab Res Rev; 2015 Sep; 31(6):610-8. PubMed ID: 25773712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
    Rayner CK; Watson LE; Phillips LK; Lange K; Bound MJ; Grivell J; Wu T; Jones KL; Horowitz M; Ferrannini E; Tricò D; Frascerra S; Mari A; Natali A
    Diabetes Care; 2020 Aug; 43(8):1813-1821. PubMed ID: 32471908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.
    Lorenz M; Pfeiffer C; Steinsträsser A; Becker RH; Rütten H; Ruus P; Horowitz M
    Regul Pept; 2013 Aug; 185():1-8. PubMed ID: 23665027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
    Meier JJ; Menge BA; Schenker N; Erdmann S; Kahle-Stephan M; Schliess F; Kapitza C; Nauck MA
    Diabetes Obes Metab; 2020 Apr; 22(4):599-611. PubMed ID: 31793165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
    Werner U
    J Diabetes Complications; 2014; 28(1):110-4. PubMed ID: 23992745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes.
    Jones KL; Rigda RS; Buttfield MDM; Hatzinikolas S; Pham HT; Marathe CS; Wu T; Lange K; Trahair LG; Rayner CK; Horowitz M
    Diabetes Obes Metab; 2019 May; 21(5):1158-1167. PubMed ID: 30623563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
    Fonseca VA; Alvarado-Ruiz R; Raccah D; Boka G; Miossec P; Gerich JE;
    Diabetes Care; 2012 Jun; 35(6):1225-31. PubMed ID: 22432104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering.
    Fleischmann H; Göke R; Bramlage P
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S91-S97. PubMed ID: 27986406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
    Riddle MC; Aronson R; Home P; Marre M; Niemoeller E; Miossec P; Ping L; Ye J; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2489-96. PubMed ID: 23628617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China.
    Men P; Li C; Zhai S; Qu S
    Curr Med Res Opin; 2020 Feb; 36(2):213-217. PubMed ID: 31469303
    [No Abstract]   [Full Text] [Related]  

  • 19. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.
    Ahrén B; Gautier JF; Berria R; Stager W; Aronson R; Bailey CJ
    Diabetes Obes Metab; 2014 Sep; 16(9):861-8. PubMed ID: 24641271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.
    McCarty D; Coleman M; Boland CL
    Ann Pharmacother; 2017 May; 51(5):401-409. PubMed ID: 28133970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.